Pharma News: Vivus, Inc. (VVUS)’s Contract, Arena Pharmaceuticals, Inc. (ARNA) & Amgen, Inc. (AMGN)’s Financial Results

Arena Pharmaceuticals Given New $11.50 Price Target at Piper Jaffray Cos. (ARNA) (MideastTime)
Equities researchers at Piper Jaffray Cos. dropped their price objective on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to $11.50 in a research report issued on Thursday, Analyst Ratings Network reports. The firm currently has an “overweight” rating on the stock. Piper Jaffray Cos.’s price objective would indicate a potential upside of 67.64% from the stock’s previous close. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) traded up 2.04% on Thursday, hitting $7.0001. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has a 52-week low of $6.65 and a 52-week high of $11.00. The stock’s 50-day moving average is currently $7.32. The company’s market cap is $1.524 billion.

Celgene Corporation (NASDAQ:CELG) and Amgen Inc. (NASDAQ:AMGN) Added to Growing Stock Report’s NASDAQ Decliners Watch List. (SBWire)
Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Celgene Corporation (NASDAQ:CELG) and Amgen, Inc. (NASDAQ:AMGN). …Amgen, Inc. (NASDAQ:AMGN) a biotechnology medicines company that engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada closed down in its previous session (-0.30%) on 2,106,197 shares traded after Amgen, Inc. (NASDAQ:AMGN) announced its financial results for the second quarter of 2013. Amgen, Inc. (NASDAQ:AMGN) is currently down (-5.79%) from its recent 52-week high which has prompted Growing Stock Report to add the stock to their NASDAQ Decliners Watch List.